|
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
MarketWatch (press release) If AstraZeneca chooses to advance the program following completion of Phase 2a, Dynavax will receive a $20 million milestone payment, and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma … |
View full post on asthma – Google News